|
|
|
 |
|
|
 |
|
|
| |
 |
| |
 |
| |
 |
|
|
Jonathan J. Fleming
- Managing General Partner
Boston, MA
Jonathan Fleming is the Managing General Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston and Connecticut.
- more
|
 |
 |
|
|
Jeffrey T. Barnes
- General Partner
Boston, MA
Mr. Barnes joined Oxford Bioscience Partners in 1999 and has over 20 years of operating and investment experience in the life sciences sector. - more
|
|
 |
|
|
Douglas M. Fambrough, Ph.D.
- General Partner
Boston, MA
Since joining Oxford in 1999, Dr. Fambrough has specialized in financing innovative life science technology companies.
- more
|
|
 |
|
|
Matthew A. Gibbs
- General Partner
Boston, MA
Mr. Gibbs joined Oxford Bioscience Partners in 1997. He has 14 years of investing experience in the healthcare and technology venture industry.
- more
|
|
 |
|
|
Michael Lytton
- General Partner
Boston, MA
Michael Lytton joined Oxford Bioscience Partners in January 2001. Prior to that, he was Partner, Chairman of the Technology Group, and a member of the Executive Committee of Palmer & Dodge LLP, a Boston-based law firm. - more
|
|
 |
|
|
Ellen S. Baron, Ph.D.
- Partner
Boston, MA
Dr. Baron is a Partner at the firm bringing significant expertise in all areas of healthcare investing, focusing principally in biotechnology. - more
|
|
 |
|
|
Edmund M. Olivier
- Senior General Partner
Costa Mesa, CA
Mr. Olivier has a profitable record of financing and managing biotechnology and healthcare investments over the last 20 years. He has been Chairman, President or Director of more than twenty life science companies.
- more
|
|
 |
|
|
Cornelius T. Ryan
- Founding General Partner
Westport, CT
Cornelius T. Ryan (Neil) co-founded Oxford Partners in 1981 and is the only partner involved in all previous Oxford funds. Neil is a Special Limited Founding Partner of Oxford Bioscience III and a General Partner of Oxford Bioscience I and II. - more
|
|
 |
|
|
Alan G. Walton, Ph.D., D.Sc.
- Senior General Partner
Westport, CT
Dr. Walton joined Oxford as a General Partner in 1987. Previously, he was President and CEO of University Genetics Co., a public biotechnology company involved in technology transfer and seed investments in university-related projects.
- more
|
|
| |
|
|
|
|
|
|
|
 |
| |
 |
|
|
David Armistead, Ph.D.
- Executive-in-Residence
Boston, MA
Dr. David Armistead joined Oxford Bioscience Partners as an Executive in Residence in 2004. Prior to joining Oxford, he was Vice President and Site Head for the Amgen Cambridge Research Center where he oversaw all aspects of the East Coast research activities for Amgen Inc. - more
|
|
 |
|
|
Oded Ben-Joseph, Ph.D., MBA
- Executive-in-Residence
Boston, MA
Dr. Ben-Joseph joined Oxford as an Executive-in-Residence in April 2007. Prior to this, he was the CEO of X-Cell Medical, an integrated drug eluting stent company.
- more
|
|
 |
|
|
James A. Bristol, Ph.D.
- Executive-in-Residence
Boston, MA
James A. Bristol, an Executive-in-Residence for Oxford Bioscience Partners, recently retired following 32 years in drug discovery research at Schering-Plough, Parke-Davis, and most recently Pfizer.
- more
|
|
 |
|
|
Robert Kamen, Ph.D.
- Executive-in-Residence
Boston, MA
Dr. Kamen joined Oxford as an Executive-in-Residence in November 2002. Prior to that, he was president of Abbott Bioresearch Center, Abbott’s immunology/oncology drug discovery and biologics production unit in Worcester, Mass. - more
|
|
 |
|
|
Manuel A. Navia, Ph.D.
- Executive-in-Residence
Boston, MA
Dr. Navia is currently an Executive-in-Residence at Oxford Bioscience Partners. He is also a consultant for a number of pharmaceutical companies in the Boston area. - more
|
|
 |
|
|
David Poorvin, Ph.D.
- Executive-in-Residence
Boston, MA
Dr. Poorvin has over 30 years of experience in the pharmaceutical industry. Most recently, Dr. Poorvin retired from Schering-Plough Corporation as Vice President of their Business Development operations where he negotiated licenses, joint ventures and acquisitions of pharmaceutical products and research technologies. - more
|
|
 |
|
|
Steven D. Targum, M.D.
- Executive-in-Residence
Boston, MA
Dr. Targum joined Oxford Bioscience Partners in 2005 as an Executive-in-Residence where he advises portfolio companies in CNS drug development.
- more
|
|
 |
|
|
Axel Unterbeck, Ph.D.
- Executive-in-Residence
Boston, MA
Dr. Axel Unterbeck joined Oxford Bioscience Partners in 2005. Prior to joining Oxford, Dr. Unterbeck was President, Chief Scientific Officer, and Co-Founder at Memory Pharmaceuticals, Corp which achieved its initial public offering in April of 2004, NASDAQ: MEMY. - more
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|